Brief: Anges And Brickell Biotech Announce A Collaboration Agreement For The Development Of A Novel DNA Vaccine Candidate For COVID-19 In U.S.

AnGes

08/09/2020 12:48

Sept 8 (Reuters) - AnGes Inc  4563.T :
    * ANGES AND BRICKELL BIOTECH ANNOUNCE A COLLABORATION
AGREEMENT
FOR THE DEVELOPMENT OF A NOVEL DNA VACCINE CANDIDATE FOR
COVID-19 IN THE U.S.
    * BRICKELL BIOTECH INC - ANGES WILL CONTINUE TO LEAD
DEVELOPMENT
OF ITS VACCINE CANDIDATE IN JAPAN
    * BRICKELL BIOTECH INC - HAS RECEIVED RIGHT TO DEVELOP AND,
IF
APPROVED, COMMERCIALIZE ANGES' DNA VACCINE IN U.S. AND CERTAIN
UNDERSERVED COUNTRIES.

Source text for Eikon:  ID:nGNX6RXSSk 
Further company coverage:  4563.T 

 ((Reuters.Briefs@thomsonreuters.com;))